Mark Lebovitch and Blair Nicholas Participate in the PLUS 2012 D&O Symposium
February 8, 2012
BLB&G partners Blair Nicholas and Mark Lebovitch participated in the PLUS 2012 D&O Symposium, which was held on February 8, 2011, in New York City.
Mr. Nicholas discussed recent developments in securities litigation as speaker on the panel entitled, “D&O Liabilities: The Latest Trends in Securities Litigation and Dodd-Frank.” Mr. Lebovitch joined the panel, “What’s new in M&A Litigation and how did we get here?” and discussed the recent explosion in M&A litigation, as well as how the litigation has evolved from what it has been historically.
Mr. Nicholas has successfully represented some of the largest institutional investors in the world in high-profile securities actions involving federal and state securities laws, accountants’ liability, and corporate governance matters. In both securities class actions and opt-out matters, he has recovered billions of dollars on behalf of mutual funds, investment advisors, public pension plans, insurance companies and hedge funds.
Mr. Lebovitch has prosecuted numerous high-profile cases on behalf of institutional investors to preliminary injunctions and to trial, obtaining hundreds of millions of dollars for investors and achieving unprecedented corporate governance improvements, including the Pfizer Derivative Litigation, the Landry’s going private litigation, and In re ACS Shareholders Litigation, among others. Most recently, he served as a co-lead trial counsel in the landmark trial challenging the Airgas Products, Inc. Board’s use of a poison pill.